Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Loss of LKB1/ STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms

Christian Marinaccio, MSc, Praveen K Suraneni, PhD, Hamza Celik, PhD, Andrew Volk, PhD, Jeremy Q. Wen, MD PhD, Te Ling, PhD, Terra Lasho, PhD, Richard P. Koche, PhD, Christopher Famulare, MS, Brady L. Stein, MD, Sandeep Gurbuxani, MBBS, PhD, Ronald Hoffman, MD, Naseema Gangat, MBBS, Navdeep Chandel, Ross L. Levine, MD, Raajit K. Rampal, MD PhD, Grant Challen, Ayalew Tefferi, MD, John D. Crispino, PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140557

Published: 2020

Journal Articles

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137749

Published: 2020

Journal Articles

Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy

Raajit K. Rampal, MD PhD, Qin Yang, Richard P. Koche, PhD, Erin McGovern, BA, Christopher Famulare, MS, Rona Singer Weinberg, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Maria E. Figueroa, MD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-139505

Published: 2020

Journal Articles

Immunophenotypic Lineage Assessment By Multiparameter Flow Cytometry Provides More Precise MDS Prognosis

Ikenna Onyekwere, BS, Julie Perilla Garcia, BS, MS, Kamal Menghrajani, MD, Alexander Chan, MD, Christopher Famulare, MS, Minal A Patel, MPH, John Philip, BA, MS, Martin S. Tallman, MD, Virginia M. Klimek, MD, Ross L. Levine, MD, Wenbin Xiao, MD PhD, Jacob L Glass, MDPhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143154

Published: 2020

Journal Articles

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

Maximilian Stahl, MD, Kamal Menghrajani, MD, Andriy Derkach, PhD, Alexander Chan, MD, Wenbin Xiao, MD PhD, Jacob L Glass, MDPhD, Amber C. King, PharmD, BCOP, Anthony Daniyan, MD, Christopher Famulare, MS, Bernadette M. Cuello, BSN, MSN, NP, RN, Omar Abdel-Wahab, MD, Ross L. Levine, MD, Aaron D Viny, MDMS, Eytan M. Stein, MD, Mikhail Roshal, MD PhD, Martin S. Tallman, MD, Aaron D Goldberg, MDPhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-137815

Published: 2020

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Xiaoli Wang, MD PhD, Raajit K. Rampal, MD PhD, Cing Siang Hu, Noushin Farnoud, PhD, Christopher Famulare, MS, Minal A Patel, MPH, Erin McGovern, BA, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1677.

https://doi.org/10.1182/blood-2019-128836

Published: 2019

Journal Articles

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Blood (2019) 134 (Supplement_1): 109.

https://doi.org/10.1182/blood-2019-122483

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

Mindy P Kresch, BS, Wenbin Xiao, MD PhD, Kamal Menghrajani, MD, Christopher Famulare, MS, Minal A Patel, MPH, Jeeyeon Baik, Mikhail Roshal, MD PhD, Ross L. Levine, MD, Martin S. Tallman, MD, Jacob L Glass, MD PhD

Blood (2019) 134 (Supplement_1): 2718.

https://doi.org/10.1182/blood-2019-131104

Published: 2019

Journal Articles

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Linde A Miles, PhD, Robert L Bowman, PhD, Tiffany R Merlinsky, Aik Ooi, PhD, Pedro Mendez, Christopher Famulare, MS, Minal A Patel, MPH, Kelly Bolton, MD PhD, Neil Palmisiano, MD MS, Martin P. Carroll, MD, Elli Papaemmanuil, PhD, Ahmet Zehir, PhD, Sara E. Meyer, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD

Blood (2019) 134 (Supplement_1): 913.

https://doi.org/10.1182/blood-2019-128763

Published: 2019

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis

Wenbin Xiao, MD, Aaron D Goldberg, MD PhD, Christopher Famulare, MS, Jeeyeon Baik, Qi Gao, Martin S. Tallman, MD, Yanming Zhang, MD, Maria E Arcila, MD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 2789.

https://doi.org/10.1182/blood-2018-99-119081

Published: 2018

Journal Articles

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

Wenbin Xiao, MD, Aaron D Goldberg, MD PhD, Brian Ball, Christopher Famulare, MS, Friederike Pastore, MD, Martin S. Tallman, MD, Yanming Zhang, MD, Maria E Arcila, MD, Elli Papaemmanuil, PhD, Ross L. Levine, MD, Mikhail Roshal, MD PhD

Blood (2018) 132 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2018-99-118985

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Chetasi Talati, MD, Aaron D Goldberg, MDPhD, Amanda Przespolewski, DO, Onyee Chan, MD, Najla Al Ali, M.Sc, Christopher Famulare, MS, David A Sallman, MD, Eric Padron, MD, Andrew Kuykendall, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Eunice S. Wang, MD, Martin S. Tallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 665.

https://doi.org/10.1182/blood-2018-99-119879

Published: 2018

Journal Articles

Small-Molecule Targeting of Musashi RNA-Binding Activity in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 428.

https://doi.org/10.1182/blood-2018-99-118745

Published: 2018

NARROW

Loss of LKB1/ STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy

Immunophenotypic Lineage Assessment By Multiparameter Flow Cytometry Provides More Precise MDS Prognosis

Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Landscape of TP53 Mutations in MPN

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis

PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy

Small-Molecule Targeting of Musashi RNA-Binding Activity in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only